Clinical Trial Update: Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 2 trial evaluating the combination of nivolumab and pemetrexed in head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pemetrexed (pemetrexed)
• nivolumab (nivolumab)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: SCCHN | Phase 2 | Status: COMPLETED